Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
SCRI Development Innovations, LLC
ClinicalTrials.gov Identifier:
NCT00915603
First received: June 4, 2009
Last updated: September 25, 2014
Last verified: September 2014

June 4, 2009
September 25, 2014
July 2009
June 2014   (final data collection date for primary outcome measure)
To assess the PFS for weekly paclitaxel/bevacizumab/everolimus and for weekly paclitaxel/bevacizumab/placebo in the first-line treatment of patients with HER2-negative metastatic breast cancer [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00915603 on ClinicalTrials.gov Archive Site
  • To assess the safety profiles of the two treatment arms [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]
  • To determine the response rates (complete response [CR] plus partial response [PR]) and rates of clinical benefit (CR + PR + stable disease [SD]) of the two treatment arms [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • To determine the duration of objective response with each of the treatment arms [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • To assess the overall survival with each of the treatment arms [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)

This randomized, double blind, placebo controlled trial will evaluate the impact of adding everolimus to the combination of weekly paclitaxel plus bevacizumab in the first-line treatment of women with HER2-negative metastatic breast cancer. Patients will be randomized (1:1) to receive either paclitaxel/bevacizumab/everolimus (Treatment Arm 1) or paclitaxel/ bevacizumab/placebo (Treatment Arm 2). Patients will be evaluated for response to treatment every 8 weeks; responding and/or stable patients will continue treatment, with re-evaluations every 8 weeks, until tumor progression or

intolerable toxicity occurs. Outcomes will be assessed for each treatment arm

separately. This trial is not intended to compare treatment arms primarily. Any such analyses are exploratory and will be conducted without adjustment for multiple hypothesis testing.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Metastatic Breast Cancer
  • Drug: Everolimus
    Everolimus 10mg PO daily continuously for all 28 days of a cycle
    Other Names:
    • Systemic therapy
    • Everolimus
    • RAD001
    • Afinitor
  • Drug: Bevacizumab
    Bevacizumab 10mg/kg IV Days 1 and 15 of 28 day cycle
    Other Names:
    • Systemic therapy
    • Bevacizumab
    • Avastin
  • Drug: Paclitaxel
    Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
    Other Names:
    • Systemic therapy
    • Paclitaxel
    • Taxol
  • Drug: Placebo
    Placebo PO daily continuously for all 28 days of a cycle
    Other Names:
    • Systemic therapy
    • Placebo
  • Drug: Bevacizumab
    Bevacizumab 10mg/kg IV days 1 and 15 of 28 day cycle
    Other Names:
    • Systemic therapy
    • Bevacizumab
    • Avastin
  • Active Comparator: paclitaxel/bevacizumab/everolimus
    Systemic Therapy
    Interventions:
    • Drug: Everolimus
    • Drug: Bevacizumab
    • Drug: Paclitaxel
  • Placebo Comparator: paclitaxel/bevacizumab/placebo
    Systemic Therapy
    Interventions:
    • Drug: Placebo
    • Drug: Bevacizumab
    • Drug: Paclitaxel
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
112
July 2014
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Female or male patients >=18 years of age.
  2. Histologically confirmed invasive breast cancer, locally unresectable or metastatic.
  3. No prior chemotherapy for MBC. Patients may have received adjuvant or

    neoadjuvant chemotherapy (including taxanes and/or bevacizumab) as long as

    treated was completed >12 months prior to relapse. Prior hormonal therapy in the

    adjuvant or metastatic setting will be permitted.

  4. Prior hormonal therapy in the adjuvant or metastatic setting is permitted. Estrogen receptor positive patients should be considered candidates for chemotherapy.
  5. HER2-negative breast cancer, defined as follows:

    • FISH-negative (FISH ratio <2.2), or
    • IHC 0-1+, or
    • IHC 2-3+ AND FISH-negative (FISH ratio <2.2).
  6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  7. Adequate hematologic function, defined by:

    · Absolute neutrophil count (ANC) >1500/mm3

    • Platelet count >=100,000/mm3
    • Hemoglobin >9 g/dL
  8. Adequate liver function, defined by:

    · AST and ALT <=2.5 x the upper limit of normal (ULN) or <=5 x ULN in

    presence of liver metastases

    • Total bilirubin <=1.5 x ULN
  9. Adequate renal function, defined by:

    · Serum creatinine <=1.5 x ULN or calculated creatinine clearance of

    >=40 ml/min

  10. International normalized ratio (INR) <=1.5 or prothrombin time (PT)/partial

    thromboplastin time (PTT) within normal limits (WNL) of the institution (if patient is not on anti-coagulation therapy). Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin are eligible if the INR is stable and within the therapeutic range prior to study treatment initiation.

  11. Adequate lipid profile: total cholesterol <=300 mg/dL OR <=7.75 mmol/L and fasting triglyceride 2.5 x ULN. Note: In case one or both of these thresholds are exceeded,the patient can only be included after initiation of appropriate lipid lowering medication.
  12. Patients with proteinuria at screening as demonstrated by either:

    · Urine protein creatinine (UPC) ration >1.0 at screening

    or

    • Urine dipstick for proteinuria >=2+ (patients discovered to have

    >=2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour

    urine collection and must demonstrate <1 g of protein in 24 hours to be

    eligible).

  13. Measurable disease by RECIST criteria.
  14. Life expectancy >=12 weeks.
  15. Ability to swallow oral medications.
  16. Adequate cardiac function, defined by baseline left ventricular ejection fraction (LVEF) value >= normal per institutional guidelines by MUGA scan or

    echocardiogram (ECHO).

  17. Adequate recovery from recent surgery.

    • Major surgical procedure >28 days from study entry
    • Minor surgical procedure >7 days from study entry (Portacath placement

    excepted - patients can start treatment <7 days after portacath placement.)

  18. Patients with previous history of invasive cancers (including breast cancer) are eligible if definitive treatment was completed more than 5 years prior to initiating current study treatment, and there is no evidence of recurrent disease.
  19. Patient must be accessible for treatment and follow-up.
  20. All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry.

    -

Exclusion Criteria:

  1. Patients with active brain metastases or meningeal metastases. Patients who have had brain metastases resected, or have received brain radiation therapy >4 weeks prior to study entry are eligible, if they meet all of the following criteria: 1) residual symptoms < grade 2, 2) no dexamethasone requirement, and 3) follow-up MRI shows regression of lesions after treatment and no new lesions appearing.
  2. Previous treatment with an m-TOR inhibitor (sirolimus, temsirolimus, everolimus) or anti-angiogenesis agent unless:

    • in the adjuvant setting, and
    • >=12 months prior to recurrence.
  3. Previous radiotherapy for metastatic disease completed <2 weeks prior to study treatment initiation.
  4. Patients who are current receiving systemic cancer therapy or have received

    previous systemic therapy within 4 weeks of the start of study drug (e.g.

    chemotherapy, antibody therapy, targeted agents).

  5. Women who are pregnant or lactating. All patients with reproductive potential must agree to use effective contraception from time of study entry until at least 3 months after the last administration of study drug.
  6. Uncontrolled hypertension defined as systolic blood pressure >150 mmHg or

    diastolic pressure >100 mmHg, despite optimal medical management.

  7. Concurrent use of CYP3A4 inhibitors and inducers from 72 hours prior to initiation of study treatment until the end of treatment with everolimus.
  8. Cardiac disease, including: congestive heart failure (CHF) > Class II per New York Heart Association (NYHA) classification; unstable angina (anginal symptoms at rest) or new-onset angina (i.e., began within the last 3 months), or myocardial infarction within the past 6 months; symptomatic CHF, unstable angina pectoris, or cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.
  9. History of stroke or transient ischemic attack within 6 months prior to first

    bevacizumab dose.

  10. Patients with any non-healing wound, ulcer, or long-bone fracture.
  11. Patients with clinical history of hemoptysis or hematemesis.
  12. Patients with any history of a bleeding diathesis or coagulopathy.
  13. Patients with a PEG or G tube cannot be enrolled into this trial.
  14. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to beginning bevacizumab.
  15. Patients with an impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
  16. Patients who have any severe and/or uncontrolled medical conditions or other

    conditions that could affect their participation such as:

    • severe impaired lung functions as defined as spirometry and DLCO that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air
    • uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN.
  17. History of any other disease, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug, or that might affect interpretation of the results of this study, or render the subject at high risk for treatment complications.
  18. History of hypersensitivity to Cremophor EL (polyoxyethylated castor oil) or a drug formulated in Cremophor EL, such as paclitaxel.
  19. Patients may not receive any other investigational or anti-cancer treatments while participating in this study.
  20. Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed.
  21. Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period.
  22. Concurrent severe, uncontrolled infection or intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
  23. Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or its excipients.
  24. Patients with a known HIV seropositivity.

    -

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00915603
SCRI BRE 154
No
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
Novartis
Study Chair: Denise A. Yardley, M.D. SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP